Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects.
- Published in:
- Diabetes Care, 2014, v. 37, n. 9, p. 2609, doi. 10.2337/dc14-0210
- By:
- Publication type:
- Article
Works by Sinha, Vikram P
Results: 13
1
2
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
- Published in:
- 2013
- By:
- Publication type:
- Letter
3
Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type2 Diabetes. Diabetes Care 2012;35: 2140-2147.
- Published in:
- Diabetes Care, 2013, v. 36, n. 7, p. e107, doi. 10.2337/dc13-0295
- By:
- Publication type:
- Article
4
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
- Published in:
- 2013
- By:
- Publication type:
- journal article
5
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes.
- Published in:
- Diabetes Care, 2013, v. 36, n. 3, p. 522, doi. 10.2337/dc12-0067
- By:
- Publication type:
- Article
6
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 7, p. 792, doi. 10.1002/jcph.276
- By:
- Publication type:
- Article
7
Single-Dose Pharmacokinetics and Glucodynamics of the Novel.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 2, p. 1, doi. 10.1002/jcph.276
- By:
- Publication type:
- Article
8
Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-β Inhibitor, in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2007, v. 47, n. 9, p. 1138, doi. 10.1177/0091270007304775
- By:
- Publication type:
- Article
9
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
- Published in:
- 2012
- By:
- Publication type:
- journal article
10
A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin--Treated PatientsWith Type 2 Diabetes.
- Published in:
- Diabetes Care, 2012, v. 35, n. 11, p. 2140, doi. 10.2337/dc12-0060
- By:
- Publication type:
- Article
11
Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 70, n. 4, p. 523, doi. 10.1111/j.1365-2125.2010.03731.x
- By:
- Publication type:
- Article
12
Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 3, p. 216, doi. 10.1002/cpdd.252
- By:
- Publication type:
- Article
13
Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism.
- Published in:
- Diabetes, 2014, v. 63, n. 2, p. 494, doi. 10.2337/db13-0826
- By:
- Publication type:
- Article